Morgan Stanley 180 Life Sciences Corp. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.12 - $1.31 $3,276 - $35,772	-27,307 Reduced 62.08%	16,677 $11,000
Q2 2022 Oct 27, 2022	SELL	$0.81 - $2.53 $3,151 - $9,844	-3,891 Reduced 8.13%	43,984 $37,000
Q2 2022 Aug 15, 2022	SELL	$0.81 - $2.53 $3,151 - $9,844	-3,891 Reduced 8.13%	43,984 $37,000
Q1 2022 Oct 27, 2022	BUY	$2.53 - $3.9 $9,844 - $15,174	3,891 Added 8.85%	47,875 $124,000
Q1 2022 May 13, 2022	SELL	$2.53 - $3.9 $85,875 - $132,377	-33,943 Reduced 41.49%	47,875 $124,000
Q4 2021 Feb 14, 2022	SELL	$3.27 - $6.38 $174,411 - $340,290	-53,337 Reduced 39.46%	81,818 $319,000
Q3 2021 Nov 15, 2021	BUY	$5.11 - $10.81 $690,642 - $1.46 Million	135,155 New	135,155 $730,000

Ticker ATNF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,698,900
Market Cap $81.1M
Description
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on f...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.